Development and validation of a risk prediction model for lost to follow-up among adults on active antiretroviral therapy in Ethiopia: a retrospective follow-up study.
HIV/AIDS
Lost to follow up
Regression formula
Risk prediction
Risk score
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
07 Sep 2022
07 Sep 2022
Historique:
received:
30
11
2021
accepted:
12
08
2022
entrez:
7
9
2022
pubmed:
8
9
2022
medline:
11
9
2022
Statut:
epublish
Résumé
Over 420,000 people have initiated life-saving antiretroviral therapy (ART) in Ethiopia; however, lost-to-follow-up (LTFU) rates continues to be high. A clinical decision tool is needed to identify patients at higher risk for LTFU to provide individualized risk prediction to intervention. Therefore, this study aimed to develop and validate a statistical risk prediction tool that predicts the probability of LTFU among adult clients on ART. A retrospective follow-up study was conducted among 432 clients on ART in Gondar Town, northwest, Ethiopia. Prognostic determinates included in the analysis were determined by multivariable logistic regression. The area under the receiver operating characteristic (AUROC) and calibration plot were used to assess the model discriminative ability and predictive accuracy, respectively. Individual risk prediction for LTFU was determined using both regression formula and score chart rule. Youden index value was used to determine the cut-point for risk classification. The clinical utility of the model was evaluated using decision curve analysis (DCA). The incidence of LTFU was 11.19 (95% CI 8.95-13.99) per 100-persons years of observation. Potential prognostic determinants for LTFU were rural residence, not using prophylaxis (either cotrimoxazole or Isoniazid or both), patient on appointment spacing model (ASM), poor drug adherence level, normal Body mass index (BMI), and high viral load (viral copies > 1000 copies/ml). The AUROC was 85.9% (95% CI 82.0-89.6) for the prediction model and the risk score was 81.0% (95% CI 76.7-85.3) which was a good discrimination probability. The maximum sensitivity and specificity of the probability of LTFU using the prediction model were 72.07% and 83.49%, respectively. The calibration plot of the model was good (p-value = 0.350). The DCA indicated that the model provides a higher net benefit following patients based on the risk prediction tool. The incidence of LTFU among clients on ART in Gondar town was high (> 3%). The risk prediction model presents an accurate and easily applicable prognostic prediction tool for clients on ART. A prospective follow-up study and external validation of the model is warranted before using the model.
Sections du résumé
BACKGROUND
BACKGROUND
Over 420,000 people have initiated life-saving antiretroviral therapy (ART) in Ethiopia; however, lost-to-follow-up (LTFU) rates continues to be high. A clinical decision tool is needed to identify patients at higher risk for LTFU to provide individualized risk prediction to intervention. Therefore, this study aimed to develop and validate a statistical risk prediction tool that predicts the probability of LTFU among adult clients on ART.
METHODS
METHODS
A retrospective follow-up study was conducted among 432 clients on ART in Gondar Town, northwest, Ethiopia. Prognostic determinates included in the analysis were determined by multivariable logistic regression. The area under the receiver operating characteristic (AUROC) and calibration plot were used to assess the model discriminative ability and predictive accuracy, respectively. Individual risk prediction for LTFU was determined using both regression formula and score chart rule. Youden index value was used to determine the cut-point for risk classification. The clinical utility of the model was evaluated using decision curve analysis (DCA).
RESULTS
RESULTS
The incidence of LTFU was 11.19 (95% CI 8.95-13.99) per 100-persons years of observation. Potential prognostic determinants for LTFU were rural residence, not using prophylaxis (either cotrimoxazole or Isoniazid or both), patient on appointment spacing model (ASM), poor drug adherence level, normal Body mass index (BMI), and high viral load (viral copies > 1000 copies/ml). The AUROC was 85.9% (95% CI 82.0-89.6) for the prediction model and the risk score was 81.0% (95% CI 76.7-85.3) which was a good discrimination probability. The maximum sensitivity and specificity of the probability of LTFU using the prediction model were 72.07% and 83.49%, respectively. The calibration plot of the model was good (p-value = 0.350). The DCA indicated that the model provides a higher net benefit following patients based on the risk prediction tool.
CONCLUSION
CONCLUSIONS
The incidence of LTFU among clients on ART in Gondar town was high (> 3%). The risk prediction model presents an accurate and easily applicable prognostic prediction tool for clients on ART. A prospective follow-up study and external validation of the model is warranted before using the model.
Identifiants
pubmed: 36071386
doi: 10.1186/s12879-022-07691-x
pii: 10.1186/s12879-022-07691-x
pmc: PMC9449961
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
727Informations de copyright
© 2022. The Author(s).
Références
BMC Res Notes. 2018 May 10;11(1):287
pubmed: 29747698
HIV AIDS (Auckl). 2015 May 28;7:167-74
pubmed: 26064071
BMC Health Serv Res. 2015 Jul 04;15:259
pubmed: 26141729
HIV AIDS (Auckl). 2021 Apr 20;13:445-454
pubmed: 33907472
Trop Med Int Health. 2008 Mar;13(3):328-33
pubmed: 18298607
PLoS One. 2018 Aug 29;13(8):e0201945
pubmed: 30157197
BMJ Open. 2013 Oct 25;3(10):e003499
pubmed: 24163204
Indian Pediatr. 2011 Apr;48(4):277-87
pubmed: 21532099
PLoS One. 2017 Jan 31;12(1):e0170893
pubmed: 28141867
J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug;7(4):193-9
pubmed: 18626124
PLoS One. 2018 Jul 11;13(7):e0200505
pubmed: 29995957
PLoS One. 2020 Jan 24;15(1):e0227473
pubmed: 31978137
BMC Res Notes. 2019 Apr 18;12(1):232
pubmed: 30999924
HIV AIDS (Auckl). 2021 Aug 11;13:801-812
pubmed: 34408500
Clin Epidemiol. 2021 Jul 31;13:637-647
pubmed: 34366681
AIDS. 2020 Jul 15;34(9):1261-1288
pubmed: 32287056
Trop Med Health. 2020 Sep 14;48:78
pubmed: 32943978
BMC Public Health. 2018 Jul 20;18(1):896
pubmed: 30029598
HIV AIDS (Auckl). 2021 Feb 17;13:205-215
pubmed: 33633468
JAMA. 2009 Jun 10;301(22):2380-2
pubmed: 19509386
PLoS One. 2015 Sep 04;10(9):e0136117
pubmed: 26340271
HIV Med. 2017 Sep;18(8):573-579
pubmed: 28150466
PLoS One. 2017 Jun 16;12(6):e0179533
pubmed: 28622361
BMC Infect Dis. 2018 Jun 18;18(1):280
pubmed: 29914400
N Am J Med Sci. 2014 Sep;6(9):453-9
pubmed: 25317390
BMC Infect Dis. 2020 Jun 22;20(1):439
pubmed: 32571232
PLoS One. 2018 Jan 26;13(1):e0188488
pubmed: 29373574
PLoS Med. 2017 Apr 18;14(4):e1002278
pubmed: 28419097
HIV AIDS (Auckl). 2016 Apr 26;8:83-92
pubmed: 27175095
BMJ. 2020 Mar 18;368:m441
pubmed: 32188600
Clin Infect Dis. 2001 Oct 15;33(8):1417-23
pubmed: 11550118
Pan Afr Med J. 2013 May 26;15:35
pubmed: 24009811
BMJ Glob Health. 2017 Aug 6;2(3):e000325
pubmed: 29082011
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
BMC Public Health. 2015 May 03;15:462
pubmed: 25934178
BMC Infect Dis. 2019 Feb 4;19(1):107
pubmed: 30717705
Curr Opin HIV AIDS. 2016 Sep;11(5):492-500
pubmed: 27254748
Science. 1988 Jun 3;240(4857):1285-93
pubmed: 3287615
BMC Res Notes. 2019 Feb 28;12(1):111
pubmed: 30819236